公开(公告)号：US20130216478A1

公开(公告)日：2013-08-22

申请号：US13854560

申请日：2013-04-01

Applicant: STC.UNM

Inventor： Jeffrey P. Norenberg ,  Richard S. Larson

IPC: C07F9/94 ,  C07F5/00 ,  A61K51/04

CPC classification number: C07F5/003 ,  A61K47/22 ,  A61K49/106 ,  A61K51/0474 ,  A61K51/0482 ,  A61K51/0485 ,  A61K51/0497 ,  C07F9/94

Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

Abstract translation: 本发明涉及用于对癌症特别是白血病和非霍奇金淋巴瘤（NHL）进行成像的新型非侵入性诊断工具，其体内毒性最小。 本发明代表了目前依赖于组织活检以诊断这些癌症的本领域的明显进步。 该新型成像探针能够检测癌前细胞，以及它们在组织中的转移扩散。 这代表了使用非侵入性分子成像技术在NHL的诊断和分期中向前推进的量子进程。 该新型探针也可用于监测患者对化疗治疗的反应和用于治疗NHL的其他干预措施或疗法。 根据本发明的化合物可以用作许多病症和疾病状态的诊断工具以及用于治疗这些病症和疾病状态的治疗剂。

公开(公告)号：US08834838B2

公开(公告)日：2014-09-16

申请号：US13854560

申请日：2013-04-01

Applicant: STC.UNM

Inventor： Jeffrey P. Norenberg ,  Richard S. Larson

IPC: A61K51/00 ,  A61M36/14 ,  C07F9/94 ,  C07F5/00 ,  A61K51/04 ,  A61K49/10

CPC classification number: C07F5/003 ,  A61K47/22 ,  A61K49/106 ,  A61K51/0474 ,  A61K51/0482 ,  A61K51/0485 ,  A61K51/0497 ,  C07F9/94

Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

Abstract translation: 本发明涉及用于对癌症特别是白血病和非霍奇金淋巴瘤（NHL）进行成像的新型非侵入性诊断工具，其体内毒性最小。 本发明代表了目前依赖于组织活检以诊断这些癌症的本领域的明显进步。 该新型成像探针能够检测癌前细胞，以及它们在组织中的转移扩散。 这代表了使用非侵入性分子成像技术在NHL的诊断和分期中向前推进的量子进程。 该新型探针也可用于监测患者对化疗治疗的反应和用于治疗NHL的其他干预措施或疗法。 根据本发明的化合物可以用作许多病症和疾病状态的诊断工具以及用于治疗这些病症和疾病状态的治疗剂。

公开(公告)号：US10031135B2

公开(公告)日：2018-07-24

申请号：US14172429

申请日：2014-02-04

Applicant: STC.UNM ,  SANDIA CORPORATION

Inventor： Richard S. Larson ,  Brian Hjelle ,  Pam R. Hall ,  David C. Brown ,  Marco Bisoffi ,  Susan M. Brozik ,  Darren W. Branch ,  Thayne L. Edwards ,  David Wheeler

IPC: G01N33/543 ,  C12Q1/6825

Abstract: Viruses and other bioagents are of high medical and biodefense concern and their detection at concentrations well below the threshold necessary to cause health hazards continues to be a challenge with respect to sensitivity, specificity, and selectivity. Ideally, assays for accurate and real time detection of viral agents and other bioagents would not necessitate any pre-processing of the analyte, which would make them applicable for example to bodily fluids (blood, sputum) and man-made as well as naturally occurring bodies of water (pools, rivers). We describe herein a robust biosensor that combines the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents. In preferred embodiments, a lithium tantalate based SAW transducer with silicon dioxide waveguide sensor platform featuring three test and one reference delay lines was used to adsorb antibodies directed against Coxsackie virus B4 or the negative-stranded category A bioagent Sin Nombre virus (SNV), a member of the genus Hantavirus, family Bunyaviridae, negative-stranded RNA viruses. Rapid detection (within seconds) of increasing concentrations of viral particles was linear over a range of order of magnitude for both viruses, although the sensor was approximately 50×104-fold more sensitive for the detection of SNV. For both pathogens, the sensor's selectivity for its target was not compromised by the presence of confounding Herpes Simplex virus type 1. The biosensor was able to detect SNV at doses lower than the load of virus typically found in a human patient suffering from hantavirus cardiopulmonary syndrome (HCPS). Further, in a proof-of-principle real world application, the SAW biosensor was capable of selectively detecting SNV agents in complex solutions, such as naturally occurring bodies of water (river, sewage effluent) without analyte pre-processing.

公开(公告)号：US20160324993A1

公开(公告)日：2016-11-10

申请号：US15214921

申请日：2016-07-20

Applicant: STC.UNM

Inventor： Jeffrey P. Norenberg ,  Richard S. Larson

IPC: A61K51/04 ,  A61K47/22

CPC classification number: C07F5/003 ,  A61K47/22 ,  A61K49/106 ,  A61K51/0474 ,  A61K51/0482 ,  A61K51/0485 ,  A61K51/0497 ,  C07F9/94

Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

Abstract translation: 本发明涉及用于对癌症特别是白血病和非霍奇金淋巴瘤（NHL）进行成像的新型非侵入性诊断工具，其体内毒性最小。 本发明代表了目前依赖于组织活检以诊断这些癌症的本领域的明显进步。 该新型成像探针能够检测癌前细胞，以及它们在组织中的转移扩散。 这代表了使用非侵入性分子成像技术在NHL的诊断和分期中向前推进的量子进程。 该新型探针也可用于监测患者对化疗治疗的反应和用于治疗NHL的其他干预措施或疗法。 根据本发明的化合物可以用作许多病症和疾病状态的诊断工具以及用于治疗这些病症和疾病状态的治疗剂。

公开(公告)号：US20190242888A1

公开(公告)日：2019-08-08

申请号：US16277618

申请日：2019-02-15

Applicant: STC.UNM ,  SANDIA CORPORATION

Inventor： Richard S. Larson ,  Brian Hjelle ,  Pam R. Hall ,  David C. Brown ,  Marco Bisoffi ,  Susan M. Brozik ,  Darren W. Branch ,  Thayne L. Edwards ,  David Wheeler

IPC: G01N33/543 ,  G01N33/553 ,  C12Q1/6825 ,  G01N29/032

CPC classification number: G01N33/54373 ,  C12Q1/6825 ,  G01N29/032 ,  G01N33/553 ,  G01N2291/0422

Abstract: Viruses and other bioagents are of high medical and biodefense concern and their detection at concentrations well below the threshold necessary to cause health hazards continues to be a challenge with respect to sensitivity, specificity, and selectivity. Ideally, assays for accurate and real time detection of viral agents and other bioagents would not necessitate any pre-processing of the analyte, which would make them applicable for example to bodily fluids (blood, sputum) and man-made as well as naturally occurring bodies of water (pools, rivers). We describe herein a robust biosensor that combines the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents. In preferred embodiments, a lithium tantalate based SAW transducer with silicon dioxide waveguide sensor platform featuring three test and one reference delay lines was used to adsorb antibodies directed against Coxsackie virus B4 or the negative-stranded category A bioagent Sin Nombre virus (SNV), a member of the genus Hantavirus, family Bunyaviridae, negative-stranded RNA viruses. Rapid detection (within seconds) of increasing concentrations of viral particles was linear over a range of order of magnitude for both viruses, although the sensor was approximately 50×104-fold more sensitive for the detection of SNV. For both pathogens, the sensor's selectivity for its target was not compromised by the presence of confounding Herpes Simplex virus type 1. The biosensor was able to detect SNV at doses lower than the load of virus typically found in a human patient suffering from hantavirus cardiopulmonary syndrome (HCPS). Further, in a proof-of-principle real world application, the SAW biosensor was capable of selectively detecting SNV agents in complex solutions, such as naturally occurring bodies of water (river, sewage effluent) without analyte pre-processing.

公开(公告)号：US20170184581A1

公开(公告)日：2017-06-29

申请号：US15411576

申请日：2017-01-20

Applicant: STC.UNM ,  SANDIA CORPORATION

Inventor： Richard S. Larson ,  Brian Hjelle ,  Pam R. Hall ,  David C. Brown ,  Marco Bisoffi ,  Susan M. Brozik ,  Darren W. Branch ,  Thayne L. Edwards ,  David Wheeler

IPC: G01N33/543 ,  G01N33/553 ,  G01N29/032 ,  C12Q1/68

CPC classification number: G01N33/54373 ,  C12Q1/6825 ,  G01N29/032 ,  G01N33/553 ,  G01N2291/0422

Abstract: Viruses and other bioagents are of high medical and biodefense concern and their detection at concentrations well below the threshold necessary to cause health hazards continues to be a challenge with respect to sensitivity, specificity, and selectivity. Ideally, assays for accurate and real time detection of viral agents and other bioagents would not necessitate any pre-processing of the analyte, which would make them applicable for example to bodily fluids (blood, sputum) and man-made as well as naturally occurring bodies of water (pools, rivers). We describe herein a robust biosensor that combines the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents. In preferred embodiments, a lithium tantalate based SAW transducer with silicon dioxide waveguide sensor platform featuring three test and one reference delay lines was used to adsorb antibodies directed against Coxsackie virus B4 or the negative-stranded category A bioagent Sin Nombre virus (SNV), a member of the genus Hantavirus, family Bunyaviridae, negative-stranded RNA viruses. Rapid detection (within seconds) of increasing concentrations of viral particles was linear over a range of order of magnitude for both viruses, although the sensor was approximately 50×104-fold more sensitive for the detection of SNV. For both pathogens, the sensor's selectivity for its target was not compromised by the presence of confounding Herpes Simplex virus type 1. The biosensor was able to detect SNV at doses lower than the load of virus typically found in a human patient suffering from hantavirus cardiopulmonary syndrome (HCPS). Further, in a proof-of-principle real world application, the SAW biosensor was capable of selectively detecting SNV agents in complex solutions, such as naturally occurring bodies of water (river, sewage effluent) without analyte pre-processing.

公开(公告)号：US09546186B2

公开(公告)日：2017-01-17

申请号：US14451916

申请日：2014-08-05

Applicant: STC.UNM

Inventor： Jeffrey P. Norenberg ,  Richard S. Larson

IPC: A61K51/00 ,  A61M36/14 ,  C07F5/00 ,  C07F9/94 ,  A61K49/10 ,  A61K51/04

CPC classification number: C07F5/003 ,  A61K47/22 ,  A61K49/106 ,  A61K51/0474 ,  A61K51/0482 ,  A61K51/0485 ,  A61K51/0497 ,  C07F9/94

Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

Abstract translation: 本发明涉及用于对癌症特别是白血病和非霍奇金淋巴瘤（NHL）进行成像的新型非侵入性诊断工具，其体内毒性最小。 本发明代表了目前依赖于组织活检以诊断这些癌症的本领域的明显进步。 该新型成像探针能够检测癌前细胞，以及它们在组织中的转移扩散。 这代表了使用非侵入性分子成像技术在NHL的诊断和分期中向前推进的量子进程。 该新型探针也可用于监测患者对化疗治疗的反应和用于治疗NHL的其他干预措施或疗法。 根据本发明的化合物可以用作许多病症和疾病状态的诊断工具以及用于治疗这些病症和疾病状态的治疗剂。

公开(公告)号：US20140341806A1

公开(公告)日：2014-11-20

申请号：US14451916

申请日：2014-08-05

Applicant: STC.UNM

Inventor： Jeffrey P. Norenberg ,  Richard S. Larson

IPC: C07F5/00

CPC classification number: C07F5/003 ,  A61K47/22 ,  A61K49/106 ,  A61K51/0474 ,  A61K51/0482 ,  A61K51/0485 ,  A61K51/0497 ,  C07F9/94

Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

Abstract translation: 本发明涉及用于对癌症特别是白血病和非霍奇金淋巴瘤（NHL）进行成像的新型非侵入性诊断工具，其体内毒性最小。 本发明代表了目前依赖于组织活检以诊断这些癌症的本领域的明显进步。 该新型成像探针能够检测癌前细胞，以及它们在组织中的转移扩散。 这代表了使用非侵入性分子成像技术在NHL的诊断和分期中向前推进的量子进程。 该新型探针也可用于监测患者对化疗治疗的反应和用于治疗NHL的其他干预措施或疗法。 根据本发明的化合物可以用作许多病症和疾病状态的诊断工具以及用于治疗这些病症和疾病状态的治疗剂。